Stereotaxis (STXS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Stereotaxis

NYSE American•Healthcare•Medical Instruments & Supplies

$1.390.00(0.00%)Market closed

Market Cap

$133.04M

P/S

4.4x

P/B

10.9x

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

How this company scores

AverageMetricSide Score: 42/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (5/25).

Profitability13/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality5/25

Strengths

Interest easily coveredProfit converts from growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 4.4x5y range 4.2x – 13.5x

Currently near its 20-quarter median.

P/B · 10.9x5y range 4.8x – 128.1x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $133.04M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $30.07M
Q. Revenue: $7.67M
TTM EBITDA: $-22.11M
TTM Op. Income: $-22.75M
Q. Op. Income: $-4.57M
TTM Net Income: $-22.32M
Q. Net Income: $-4.47M
EPS: $-0.05
Shares Out.: $100.03M

$30.07M in TTM revenue declined 5.5% YoY, reaching $7.67M last quarter. TTM EBITDA of $-22.11M and TTM operating income of $-22.75M show growth is flowing through to the bottom line. However, net income is negative at $22.32M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.5%
EBITDA Margin: -57.3%
Op. Margin: -59.6%
Net Margin: -58.3%

Op. margin of -59.6% is down 14.4% YoY — costs are rising relative to revenue. Net margin at -58.3% and gross margin of 58.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 32% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 4.4x
P/B Ratio: 10.9x

P/S of 4.4x and P/B of 10.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $55.58M
Cash: $10.49M
Long-Term Debt: N/A
Book Value: $12.24M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-3.67M
TTM Free Cash Flow: $-15.50M
FCF Margin: -51.6%
FCF / Net Income: 0.7

TTM FCF of $-15.50M on $-3.67M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 80% — an improving trend.